p16和HPV DNA检测在ASC-US分流中的价值研究

doi:10.3969/j.issn.1000-8535.2022.04.008

广州医药 ›› 2022, Vol. 53 ›› Issue (4): 30-35.DOI: 10.3969/j.issn.1000-8535.2022.04.008

p16和HPV DNA检测在ASC-US分流中的价值研究

游伟强¹, 王莉平¹, 吴小延², 叶才果³, 方小龙¹, 林立鹏¹

1 深圳市福田区妇幼保健院检验科(深圳 518016)
2 中山大学肿瘤防治中心分子诊断科(广州 510060)
3 广东医科大学广东省医学分子诊断重点实验室(东莞 523808)

收稿日期:2021-09-10 出版日期:2022-07-20 发布日期:2022-08-03
通讯作者: 王莉平,E-mail:1758213301@qq.com
基金资助:
国家自然科学基金(81572782);广东省医学科学技术研究基金(A2021379)

Value of p16 and HPV DNA detection in ASC-US shunt

YOU Weiqiang¹, WANG Liping¹, WU Xiaoyan², YE Caiguo³, FANG Xiaolong¹, LIN Lipeng¹

1 Department of Clinical Laboratory, Shenzhen Futian District Maternity and Child Healthcare Hospital,Shenzhen 518016,China
2 Department of Molecular Diagnosis,Sun Yat-sen University Cancer Center,Guangzhou 510060, China
3 Key Laboratory of Medical Molecular Diagnosis,Guangdong Province Affiliated to Guangdong Medical University,Dongguan 523808,China

Received:2021-09-10 Online:2022-07-20 Published:2022-08-03

摘要/Abstract

摘要： 目的探讨p16免疫细胞化学、人乳头瘤病毒(HPV)DNA基因分型单独和联合检测在宫颈细胞学不能明确诊断意义的非典型鳞状上皮细胞(ASC-US)分流中的价值。方法收集2017年3月—2022年1月,585例液基薄层细胞学(TCT)诊断为ASC-US患者的宫颈细胞学标本,使用免疫细胞化学法行p16蛋白检测,生物芯片法行HPV DNA基因分型检测,患者于8周内行阴道镜下病理活检术。以组织学诊断结果为金标准,探讨p16免疫细胞化学和HPV DNA基因分型单独和联合检测方法在同一级别宫颈病变中阳性率的差异,对比同一检测方法在不同级别宫颈病变中阳性率的差异,比较p16免疫细胞化学、HPV DNA基因分型单独和联合检测对高级别鳞状上皮内病变(HSIL)以上病变诊断效能的差异,综合评定一种最优的ASC-US分流方法。结果 ①(p16+HPV DNA)联合检测在同一级别宫颈病变中阳性率高于p16免疫细胞化学、HPV DNA基因分型检测。②p16免疫细胞化学、HPV DNA基因分型、(p16+HPV DNA)联合检测的阳性率均随着宫颈病变程度的加重而递增。③(p16+HPV DNA)联合检测的综合诊断效能最佳,其灵敏度、特异度、符合率和约登指数分别为99.07%、62.55%、69.23%、0.62。结论 p16免疫细胞化学检测法与HPV DNA基因分型单独和联合检测均有助于ASC-US分流,但是,(p16+HPV DNA)联合检测具有更优的灵敏度和约登指数,同时保持了较高的特异度和符合率,可有效进行ASC-US分流。

关键词: p16蛋白, 免疫细胞化学, 人乳头状瘤病毒, 不能明确诊断意义的非典型鳞状上皮细胞, 宫颈上皮内瘤变, 宫颈癌

Abstract: Objective To investigate the value of p16 immunocytochemistry and human papillomavirus (HPV) DNA genotyping alone and combined in atypical squamous cells of undetermined significance (ASC-US) shunt which cervical cytology can not clearly diagnose. Methods From March 2017 to January 2022, cervical cytological specimens of 585 patients with ASC-US diagnosed by liquid based thinprep cytology test (TCT) were collected. p16 protein was detected by immunocytochemistry, HPV DNA genotype was detected by biochip and the patients underwent colposcopy pathological biopsy within 8 weeks. Taking the histological diagnosis results as the gold standard, the differences of the positive rate of p16 immunocytochemistry and HPV DNA genotyping in the same level of cervical lesions, differences of the positive rate of the same detection method in different levels of cervical lesions and differenes of p16 immunocytochemistry HPV DNA genotyping alone and combined detection of the diagnostic efficacy of lesions severer than high-grade squamous intraepithelial lesion (HSIL) were compared to comprehensively evaluate an optimal ASC-US shunt method. Results ①The positive rate of combined detection of (p16+HPV DNA) in the same level of cervical lesions was higher than that of differences of p16 immunocytochemistry and HPV DNA genotyping. ②The positive rate of combined detection of (p16+HPV DNA), p16 immunocytochemistry and HPV DNA genotyping increased with the aggravation of cervical lesions. ③The combined detection of (p16+HPV DNA) had the best comprehensive diagnostic efficiency and its sensitivity, specificity, coincidence rate and Yoden index were 99.07%, 62.55%, 69.23% and 0.62 respectively. Conclusions p16 immunocytochemical assay and HPV DNA genotyping, both alone and in combination, contributed to ASC-US shunt. However, the combined detection of (p16+HPV DNA) had better sensitivity and Yoden index, with high specificity and coincidence rate, which can effectively carry out ASC-US shunt.

Key words: p16 protein, immunocytochemistry, human papillomavirus, atypical squamous cells of undetermined significance, cervical intraepithelial neoplasia, cervical carcinoma

游伟强, 王莉平, 吴小延, 叶才果, 方小龙, 林立鹏. p16和HPV DNA检测在ASC-US分流中的价值研究[J]. 广州医药, 2022, 53(4): 30-35.

YOU Weiqiang, WANG Liping, WU Xiaoyan, YE Caiguo, FANG Xiaolong, LIN Lipeng. Value of p16 and HPV DNA detection in ASC-US shunt[J]. Guangzhou Medical Journal, 2022, 53(4): 30-35.

参考文献

[1] AKKOL E K,DERELI F T G,SOBARZO-SÁNCHEZ E,et al. Roles of medicinal plants and constituents in gynecological cancer therapy: current literature and future directions[J]. Curr Top Med Chem,2020,20(20):1772-1790.
[2] RISLEY C,CLARKE M A,GEISINGER K R,et al. Racial differences in HPV type 16 prevalence in women with ASCUS of the uterine cervix[J]. Cancer Cytopathol,2020,128(8):528-534.
[3] 中国优生科学协会阴道镜和宫颈病理学分会专家委员会. 中国子宫颈癌筛查及异常管理相关问题专家共识(一)[J]. 中国妇产科临床杂志,2017,18(2):190-192.
[4] SRIVASTAVA A N,MISRA J S. ASCUS (atypical squamous cells of undetermined significance) in the cervical smears of women from rural population of Lucknow West[J]. J Obstet Gynaecol India,2019,69(2):165-170.
[5] GOTHWAL M,NALWA A,SINGH P,et al. Role of cervical cancer biomarkers p16 and Ki67 in abnormal cervical cytological smear[J]. J Obstet Gynaecol India,2021,71(1):72-77.
[6] 曹洁琼,王晓宇. p16,E6/E7蛋白与宫颈癌及癌前病变相关性的研究进展[J]. 临床与病理杂志,2020,40(2):443-447.
[7] WANG M,HOU B,WANG X,et al. Diagnostic value of high-risk human papillomavirus viral load on cervical lesion assessment and ASCUS triage[J]. Cancer Med,2021,10(7):2482-2488.
[8] 刘晓旭,梁建梅. HPV DNA和HPV E6/E7 mRNA检测在宫颈病变诊治中应用价值的比较[J]. 国际妇产科学杂志,2021,48(4): 462-466.
[9] MOYER A B,EL-ZAATARI Z M,THRALL M J. The effects of the Bethesda System 2014 on endometrial cell reporting and follow-up endometrial biopsies in women 45 years of age and over[J]. Oncol Res Treat,2018,7(4):201-204.
[10] 中华医学会. 临床技术操作规范病理学分册[M]. 北京:人民军医出版社,2012:27-33,37-40.
[11] 卢珊珊,沈丹华. 第5版WHO女性生殖器官肿瘤分类的更新及解读[J]. 中华妇产科杂志,2021,56(8):588-592.
[12] GOEL G,HALDER A,JOSHI D,et al. Rapid,economic,acetic acid papanicolaou stain (REAP):An economical,rapid and appropriate substitute to conventional pap stain for staining cervical smears[J]. J Cytol,2020,37(4):170-173.
[13] LIU Y,MCCLUGGAGE W G,DARRAGH T M,et al. p16 immunoreactivity correlates with morphologic diagnosis of HPV-associated anal intraepithelial neoplasia:A study of 1000 biopsies[J]. Am J Surg Pathol,2021,45(11):1573-1578.
[14] 中国抗癌协会妇科肿瘤专业委员会. 子宫颈癌诊断与治疗指南(2021年版)[J]. 中国癌症杂志,2021,31(6):474-489.
[15] ABDULAZIZ A M A,LIU L,SUN Y,et al. Clinicopathologic significance and treatment of ASC-US in cervical cytology[J]. Int J Clin Exp Pathol,2020,13(2):307-316.
[16] KUROKI H,SAKAMOTO J,SHIBATA T,et al. Comparison of Aptima and hybrid capture-2 HPV tests and Pap test in the referral population in Japan[J]. J Med Virol,2021,93(8):5076-5083.
[17] 陈飞,任琛琛,杨立,等. HPV E6/E7 mRNA,p16/Ki67检测在ASCUS中的诊断价值[J]. 现代妇产科进展,2019,28(1):53-57.
[18] 蔡春芳,易丹妮,郭芝亮,等. P16蛋白与TCT、HR-HPV的相关性及对不同子宫颈病变诊断的效能[J]. 山东大学学报(医学版),2022,60(1):40-47.
[19] 刘晓旭,梁建梅,苏学艳,等. HPV DNA和HPV E6/E7 mRNA检测在宫颈病变诊治中应用价值的比较[J]. 国际妇产科学杂志,2021,48(4):462-466.
[20] SONG F,BELINSON J L,YAN P,et al. Evaluation of p16 INK4a immunocytology and human papillomavirus (HPV) genotyping triage after primary HPV cervical cancer screening on self-samples in China[J]. Gynecol Onco,2021,162(2):322-330.

p16和HPV DNA检测在ASC-US分流中的价值研究

Value of p16 and HPV DNA detection in ASC-US shunt

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

本文评价

[1]	徐双, 周锋, 范娜. 超声引导下宫颈癌根治术的应用效果及对患者远期生存率的影响[J]. 广州医药, 2021, 52(5): 64-68.
[2]	朱清红, 陈小君, 甘庆权. 千伏锥形束CT(kV-CBCT)图像引导宫颈癌放射治疗的三维摆位误差分析[J]. 广州医药, 2021, 52(5): 113-116.
[3]	邓雨果, 黄子健. 核苷类似物治疗宫颈人乳头瘤病毒感染的疗效[J]. 广州医药, 2021, 52(2): 11-16.
[4]	蔡蘅, 江少如. 腹腔镜下早期宫颈癌根治术与开腹手术的临床疗效评价[J]. 广州医药, 2021, 52(2): 127-130.
[5]	吴俐俐, 杨文丰. 妇科门诊宫颈癌高危人群采取阴道镜检查后配合宫颈细胞学检查对宫颈癌筛查临床价值[J]. 广州医药, 2017, 48(5): 78-80.
[6]	张月桃, 陈中文, 王斌, 胥琳璟. 鳞癌抗原表达对宫颈癌手术治疗后临床转归的预测价值[J]. 广州医药, 2017, 48(4): 104-106.
[7]	江淑意, 刘微华, 梁惠玲. 追踪护理模式对中青年保留神经宫颈癌根治术后膀胱功能的影响[J]. 广州医药, 2017, 48(3): 86-88.
[8]	林悦欢, 胡璐萍, 何慧仪, 伍华玲. Bcl-2、COX-2在宫颈癌新辅助化疗前后的表达及临床意义的研究[J]. 广州医药, 2016, 47(6): 6-9.
[9]	李明尧, 朱土福, 张春宁. 注射用黄芪多糖对宫颈癌化疗患者骨髓抑制的效果分析[J]. 广州医药, 2016, 47(5): 36-38.
[10]	沈蓉, 吴晓玲, 胡晓燕, 龙义国. E2F-1与p16在宫颈上皮内瘤变和宫颈鳞癌中的表达及临床意义[J]. 广州医药, 2016, 47(3): 14-16.
[11]	陈能, 唐蔚. 南沙区宫颈癌HPV筛查认知研究[J]. 广州医药, 2016, 47(2): 95-95.